Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- New EA Pharma CEO Eager to Put Company Back on Growth Track by Boosting Its Sales Strength
November 5, 2021
- Nippon Shinyaku Establishes Local Subsidiary in Beijing
November 5, 2021
- Ferring, Fuji Pharma Tie Up for Cervical Ripening Agent Propess
November 5, 2021
- Enhertu Application Accepted in Europe for 2nd Line Gastric Cancer: Daiichi Sankyo/AZ
November 5, 2021
- Plunge in COVID-19 Cases Stalling Japan Avigan Study by Few Months
November 5, 2021
- Otsuka’s In-Vitro Diagnostic for ALL Now under Health Coverage
November 4, 2021
- Axcelead Inks Research Pact with Kyowa Kirin, xFOREST on Drugs Targeting RNA Structures
November 4, 2021
- Fuji Pharma Files Contraceptive in Thailand
November 4, 2021
- Mitsubishi Tanabe Sales Rise 1.9% in 1st Half on Stelara Growth at Home
November 4, 2021
- 7 Major Japan Drug Makers Net Two-Digit Growth in Combined H1 Sales on Flagship Brands, Upfront Income
November 4, 2021
- LEO Pharma Japan Taps Ex-Sanofi Exec Kazushige Sakamoto as New Chief
November 4, 2021
- Mitsubishi to Mull Domestic Manufacturing of COVID-19 Vaccine: Exec
November 4, 2021
- Mitsubishi Tanabe Ditches Flu Vaccine Candidate MT-2271
November 4, 2021
- Mari Nogami to Helm GSK Consumer Healthcare Japan
November 2, 2021
- Ono to Decide on Revision of Scholarship Donation Program by Year-End
November 2, 2021
- Kyowa Kirin’s January-September Sales Up 8.5% on Buoyant Global Products
November 2, 2021
- ASKA, RaQualia Ink New Joint Research Pact Targeting Ion Channels
November 2, 2021
- Ex-BMS Exec Masako Futagami to Head AZ Japan’s Respiratory, Immunology Biz
November 2, 2021
- Ono Enjoys Double-Digit Growth in H1 on Upbeat Opdivo, Forxiga
November 2, 2021
- Eisai’s H1 Sales Rise 14.3% on 4 Global Brands, ADC License Income
November 2, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…